If the number of patients entering the trial were infinitely large, random allocation would suffice to ensure that the two groups of patients were comparable. In most centres, however, the number of patients available for the trial is such that the usually adopted system of random allocation may not produce two groups of patients comparable in all respects. This point becomes of increasing importance when the trial is extended to include as many patients as possible.
The conclusions which may be drawn from a trial apply only to the category or categories of patients included in the trial. If only one welldefined category is used to test the value of the treatment methods, comparable groups ofpatients will be obtained without much difficulty but the trial will be of limited value. When several categories, differing say in respect of age and extent of disease, are included the value of the trial is greatly enhanced. With the number of patients usually available, more elderly patients or more patients with advanced disease may be included in one of the groups. Such a distribution could easily result in a wrong conclusion being reached. This difficulty can be overcome by adopting a more refined method of randomization.
When the trial was being designed in Edinburgh it was decided to take the age of the patient and the extent of the disease into account.
Three age groups were recognized: (1) 35-44 years.
(2)45-59 years. (3) 60-69 years.
Staging is a convenient method of grouping together patients with disease of comparable extent and all patients accepted for the trial have been subdivided as follows: (1) Stage I cases.
(2) Stage II cases. (3) The less advanced cases in Stage III.
This makes three subdivisions in respect of age and three in respect of the extent of disease, or nine categories in all. To ensure equal distribution of each of the nine categories in the two groups of patients treated, the sealed envelopes are distributed in nine boxes. In each box there are an equal number of cards inscribed with the two methods of treatment. The method of random allocation of treatment in any patient still remains quite simple. Given the age of the patient and the stage of the disease, a card is withdrawn from the appropriate box.
From the numbers so far referred it has been estimated that approximately 100 patients will be admitted to the trial each year. Bearing in mind the overriding condition that all patients must be equally suitable for either method of treatment, the investigation has been extended to cover as wide a range of patients as possible. At the same time it would appear that the method of randomization adopted will ensure that the two groups of patients will be as nearly comparable as it is possible to make them.
Dr D A G Galton (Chester Beatty Research Institute, London)
Clinical Trials in Progress: Leukemia and Multiple Myeloma The first therapeutic trials in leukemia were begun in September 1959 by a working party set up by the Medical Research Council under the Chairmanship of Professor L J Witts.1 There are 14 participating centres, some of which operate through several co-operating hospitals. Seven trials have been started; two have been completed, one was redesigned, and four are in progress.
Chronic Granulocytic Leukemia
The main trial, a comparison of busulphan and radiation in the treatment of chronic granulocytic leukvmia, is still in progress. Until February 1964 splenic irradiation was used for the 'radiotherapy' patients, but has since been replaced by radioactive phosphorus administered intravenously. This long-term trial has run very smoothly, and loss to follow up, through removal from the district, or death from unrelated causes, has been infrequent. But the disease is rare, and the rate of entry low. In the first five years only 117 cases were notified; 2 had to be rejected because of diagnostic error, and 2 because death occurred before treatment was started, within a preselected period of forty-eight hours of admission to the trial.
Only untreated patients are accepted, and some of these may have to be excluded for various reasons, usually non-medical. For example, the 50 % chance of allocation to a radiotherapy schedule has to be considered in the case of wageearning patients referred from a distance. The frequent attendances necessary for radiotherapy would involve unnecessary hardship, for these patients could be equally well treated locally by busulphan. On the other hand, many eligible patients for whom inclusion in the trial would involve no hardship are certainly being lost to the trial, and many who are referred are ineligible because they have already received chemotherapy. Acute Leuka?mia Separate trials have been designed for children (below 14 years of age) and adults (above age 14). The aim of the first trials in children and adults was to compare the effect of 6-mercaptopurine, administered at a standard daily dosage of 2-5 mg per kg of body weight in combination with prednisone at high (250 mg daily) and low (40 daily) dosage. In the first trial in adults (108 cases) the combination of mercaptopurine and prednisone at high dosage proved to be harmful (Medical Research Council 1963) , and a second trial, in which a schedule of prednisone alone, at low dosage, was substituted for it, was carried out in 150 cases. The effect of this schedule appeared to be at least as good as that of mercaptopurine alone, or the combination of mercaptopurine and prednisone, and a third trial was therefore arranged in which all the patients were to begin treatment with prednisone alone, and to receive either mercaptopurine or azathioprine when they relapsed or if they failed to respond. This trial, still in progress, is designed to see if azathioprine has any advantage over mercaptopurine.
The first trial in children was hampered by the very slow rate of entry, only 39 cases having been admitted in three years. A second trial, now in progress, was begun in which remissions were to be induced with a combination of prednisone and mercaptopurine. In one half of the cases the treatment with mercaptopurine was to be continued until it was no longer effective, when it was to be replaced by methotrexate; in the other half, the two antimetabolites were to be alternated at eight-week intervals even if remission was maintained, this method having given good results in the hands of Zuelzer & Flatz (1960) . In the hope of increasing the rate of entry, a separate Paediatric Subcommittee has been formed under the Chairmanship of Professor Wilfrid Gaisford.1
In all the leukemia trials, previous therapy other than blood transfusion, antibiotics or hematinics precludes admission.
Myelomatosis
Evidence is accumulating (Hoogstraten 1964 , Korst et al. 1964 that the continuous administration of alkylating agents may prolong the lives of patients suffering from myelomatosis, as well as conferring symptomatic benefit (Matthias 1964 , Speed et al. 1964 ) and reducing the concentration of the myeloma proteins in the serum (Waldenstrom 1964). A comparative trial of melphalan and cyclophosphamide was begun in October 1964. Palliative local irradiation of one site is not a bar to admission, and the irradiation of painful sites may be used as required during the course of the illness. Because of a general belief that chemotherapy is beneficial, the inclusion of a control group of patients was not thought to be justified, except by one member of the working party, one half of whose patients, selected at random, will not receive chemotherapy. In all the trials, the clinician is free to depart from the treatment schedule allocated, if the needs of the patients seem to require a change of therapy.
PROBLEMS OF THE TRIALS
Criteria ofEligibility Several problems common to all therapeutic trials have arisen in these trials also. The clinical variants of leukimia, like other clinical entities, are abstractions and the manifestations of any one of them are never quite the same in any two cases. The range of variation in a group of cases in a clinical trial is determined by the criteria for diagnosis and eligibility; the more rigid the criteria, the more exclusive and artificial the group will be. On the other hand, when the criteria are too broad the chance of admitting atypical cases increases, and the resulting group will no more reflect the range of the disease in the general population than that selected by rigid criteria.
There is no solution to this problem, and we have come to rely on the pragmatic test of whether, on the evidence available to him, the clinician believes that the patient in question should receive treatment appropriate to the disease under consideration. In practice, very few cases in any of the trials have had to be rejected after admission because of diagnostic errors, though there have been a few in which there was room for debate. It is likely, too, that cases excluded at some centres would have been considered eligible at others.
Diagnostic Criteria
Our chief problems so far have arisen in acute leukaemia, where the diagnosis depends on descriptive cytology. Before the trials began, a typing party tried to devise a practical classification and nomenclature of the leukaemias. Specimens of Romanowsky-stained blood and bone-marrow films from over 100 consecutive cases were circulated, and it was soon realized that the large subjective element in diagnosis presented a formidable problem. It was thought important to separate the lymphoblastic type from the others, but in planning the therapeutic trials it was decided to include all the 'myeloid' variants as a single group, a decision later vindicated by the statistical analysis of cytological characteristics published by Hayhoe et al. (1964) , in which the lymphoblastic disease was found to be distinct from the 'myeloid' subtypes which merged into one another.
A collection of bone-marrow films stained by May-Grunwald-Giemsa and by several cytochemical methods is being kept by Dr Hayhoe, but in about one-fifth of the cases, in which bonemarrow examination had been performed before the diagnosis was made or before the patient was referred for inclusion in the trial, pre-treatment films are not represented. An attempt is made to classify every case as lymphoblastic or 'myeloid', but differences of opinion still arise in about 10% of the cases, and a few undifferentiated cases defy classification, though Dr Hayhoe believes that every case could be classified if sufficient material were available for proper cytological examination. In practice, the need to begin treatment as soon as possible and the uncertainty of cytological diagnosis make it impossible to select the cases according to their cytological type before allocating them to a treatment schedule. Thus our series of adult cases is a mixture of 'myeloid' and lymphoblastic cases in a ratio of more than 5 to 1.
In the myelomatosis trial, bone-marrow films are also kept by Dr Hayhoe; in addition, Dr J R Hobbs at Hammersmith Hospital is keeping specimens of serum and urine, collected before the start of treatment and at three-monthly intervals thereafter. He is making detailed studies of the changes in the normal and 'myeloma' proteins present in the serum, and of the proteins excreted in the urine. All participants are supplied with stamped addressed specimen boxes for the dispatch of pathological specimens.
Analysis ofResults
Some of our problems are those of clinical trials in general. The material can be analysed statistically only if it is properly collected. The more items of information requested, the greater is the likelihood that the final records will be incomplete, so it is safer to budget for the smallest number of items consistent with the requirements of the trial.
In analysing the influence of therapy in acute leuklemia, the effect on survival is relatively simple to assess. The effect on the quality of survival is more difficult to express. American workers have used a precise numerical system (Bisel 1956 ) for recording the response to treatment in terms of its capacity to relieve symptoms, to influence signs, and to induce changes in the peripheral blood and bone marrow. This system is of great value in assessing the remission rate in childhood leukemia (Heyn et al. 1960 ) but has been difficult to apply to acute leukemia in adults, for which we are still seeking a satisfactory method of classifying the results of treatment. In chronic granulocytic leukamia, assessment based on clinical and hlmatological criteria as well as on survival is practicable, and in myelomatosis radiological and biochemical observations will be used also.
Organization Problems At least two full meetings of the working party are necessary each year for arriving at major decisions on the conduct of the trials. The detailed planning is done by a steering committee which meets when necessary. The design of record forms is of special importance, for the analysis of the results depends entirely on the accuracy with which the forms are completed. Therefore drafts are repeatedly submitted to all participants for criticism and amendment until they are generally approved. Even then deficiencies usually emerge during the course of the trial. Day-to-day problems that arise constantly are dealt with by telephone and correspondence, and all the participants are involved in a good deal of extra work. It is very rewarding work, and I think all my colleagues would agree that we have learned a great deal from the co-operative effort. A specially gratifying result is that the discipline imposed by the demands of the trials has greatly improved our standards of care for the patients.
